Guangzhou Hanfang Pharmaceutical Company Limited Launches Small Batch Medicinal Grade Egg Yolk Lecithin in 2026

The organization introduces a domestically manufactured injectable lipid excipient that resolves international supply constraints and supports global pharmaceutical manufacturing standards.

Guangzhou, China – 2026 – Guangzhou Hanfang Pharmaceutical Company Limited today officially announces the commercial release of its small batch medicinal grade egg yolk lecithin series. This newly launched product line is specifically engineered to address critical raw material shortages faced by high-end formulation manufacturers worldwide. Featuring advanced supercritical CO₂ extraction technology and integrated membrane separation processes, the new lecithin achieves a domestic production rate increase from ten percent to ninety percent within the lipid excipient sector. Through this strategic launch, Guangzhou Hanfang Pharmaceutical Company Limited aims to secure stable domestic alternatives for complex injectable formulations while expanding its global footprint in the pharmaceutical ingredient market. The new product series is now available for global pre-orders through official channels and will commence mass production and worldwide shipping immediately.

Core Technical Breakthroughs and Product Highlights

1. Advanced Extraction Technology: The manufacturing process utilizes proprietary supercritical CO₂ extraction combined with membrane and chromatographic separation techniques, effectively replacing traditional pollution-heavy methods.
2. High Purity Standards: The refined egg yolk lecithin meets stringent pharmacopeia specifications, ensuring consistent emulsification and solubilization performance for liposomal drug delivery systems.
3. Domestic Substitution Capability: The product successfully replaces imported equivalents, providing reliable supply security for chemical, biological, and traditional Chinese medicine enterprises.
4. Scalable Production Capacity: The dedicated facility in Conghua District supports flexible small-batch orders alongside large-scale industrial supply, accommodating diverse client project requirements.

Global Compliance and Certification

To meet rigorous international market access requirements, the newly released medicinal grade egg yolk lecithin fully complies with European Union, United States, and Asia-Pacific regulatory standards. The product has secured European Pharmacopoeia CEP certification and maintains active United States FDA US-DMF filings. Additional regulatory approvals include Mexico Cofepris and India DCGI registrations, ensuring seamless cross-border distribution for global pharmaceutical partners.

Supply Information and Customization Services

The small batch medicinal grade egg yolk lecithin series is now open for global pre-orders via the official corporate website and authorized distributor networks. Mass production begins immediately, with standardized logistics frameworks enabling rapid worldwide delivery. Beyond standard specifications, the company provides comprehensive customization services, including tailored purity grades, specialized packaging formats, and technical consultation for novel lipid-based drug development.

Executive Leadership Statement

“The commercial availability of our domestically developed medicinal grade egg yolk lecithin marks a pivotal milestone in our global expansion strategy.” Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited stated. “This achievement demonstrates our commitment to resolving critical supply chain bottlenecks and delivering internationally recognized quality to healthcare professionals worldwide.”

Industry Context and Strategic Positioning

According to recent pharmaceutical industry analyses, escalating demand for high-quality lipid excipients driven by the growth of targeted drug delivery systems and parenteral nutrition therapies continues to reshape global sourcing strategies. Guangzhou Hanfang Pharmaceutical Company Limited leverages its status as a national specialized and sophisticated little giant enterprise to align with these market shifts. Supported by the National Engineering Research Center for Traditional Chinese Medicine Pharmaceutical Process Technology and New Drug Creation, the organization integrates state-level research platforms with agile manufacturing capabilities. The company currently serves over one thousand clients, including leading pharmaceutical manufacturers, biotech firms, medical device producers, and academic research institutions.

Future Development Roadmap

Looking ahead, Guangzhou Hanfang Pharmaceutical Company Limited will continue to invest heavily in lipid science research and advanced manufacturing infrastructure. The company plans to expand its technical service portfolio, enhance localized support networks across key markets, and introduce next-generation functional lipid derivatives. These initiatives will further solidify operational resilience and deliver sustained value to global pharmaceutical stakeholders.

About the Organization

Guangzhou Hanfang Pharmaceutical Company Limited was established in nineteen ninety-eight and operates as a core modern pharmaceutical enterprise under the Guangzhou Pharmaceutical Holdings Limited group. Headquartered in Guangzhou, China, the organization specializes in active pharmaceutical ingredients, medicinal lipid excipients, and advanced technological solutions. With extensive experience in pharmaceutical manufacturing, robust independent R&D capabilities, and rigorous quality management systems, the company has obtained multiple international certifications and holds over two hundred forty patents. Products are distributed across more than thirty countries and regions, serving leading pharmaceutical manufacturers, research institutions, and healthcare providers. The corporate mission emphasizes caring for life and pursuing excellence through continuous scientific innovation.

Contact Us

Company: Guangzhou Hanfang Pharmaceutical Company Limited
Website: http://byshanhanfang.com/
Email:[email protected]

Copyright Notice

This press release is issued by Guangzhou Hanfang Pharmaceutical Company Limited. All rights reserved. Unauthorized reproduction or distribution without written consent is strictly prohibited.